We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New sPCR Technology Runs on Standard Devices

By LabMedica International staff writers
Posted on 24 Apr 2017
Image: A comparison of analytical PCR procedures (Photo courtesy of Scientific Reports).
Image: A comparison of analytical PCR procedures (Photo courtesy of Scientific Reports).
Synergistic PCR (sPCR), a new method of DNA analysis developed for use on a new high-speed assay device, can also be carried out on widely available laboratory real-time PCR (qPCR) instruments and does not require calibration.

While developing a record high-speed genetic research tool, Curiosity Diagnostics (CD; Warsaw, Poland), a spinoff company of the Warsaw Institute of Physical Chemistry of the Polish Academy of Sciences (IPC PAS) and part of the Scope Fluidics group, has developed the new sPCR method, which combines key advantages of the two currently most used methods.

"The DNA assay technique we propose was born during the development of the innovative PCR|ONE analytical instrument, which can be used to test the genetic code in only 7 minutes. This is more than 10-fold shorter time than is required in classic solutions," said Prof. Piotr Garstecki (IPC PAS, CD).

PCR is used both to detect specific DNA fragments and to estimate the original amount of genetic material. In quantitative PCR (qPCR) measurements are usually carried out using real-time PCR – an analogue technique. Due to the sensitivity of PCR to even single particles of impurities, qPCR requires careful, continuous calibration. Conversely, in digital PCR (dPCR) there is no need to calibrate the device, however, because of the need to conduct a large number of reactions in parallel, the testing equipment is expensive and is not as common in laboratories as the analogue apparatus.

sPCR combines the most important advantages of analogue and digital methods to obtain reliable measurements: it is sufficient to dilute a sample into only a dozen or at most several dozen partitions, and calibration is not required.

"A small number of partitions, characteristic of our technique, are of specific practical significance. It means that to perform the analysis all that is needed is the standard well plate format used in popular analogue PCR devices," said Pawel Debski, an IPC PAS PhD student who developed the sPCR method with Curiosity Diagnostics.

Also due to a small number of sample partitions, the sPCR technique is easier to perform and slightly faster than digital variants. Compared to analogue techniques, however, more reagents are required, and so it will not replace the analogue variant. Nevertheless, sPCR could be a valuable addition, as it requires no calibration and so will allow laboratory staff to independently and regularly check the correctness of analogue measurements.

sPCR was developed as an integral component of PCR|ONE, an innovative device designed for rapid DNA analysis. In standard PCR machines, relatively slow heat diffusion between the sample and an adjacent large block of alternately heated or cooled material is used to heat and cool the genetic material. In PCR|ONE, infrared radiation is used to heat the sample rapidly. The diffusion cooling mechanism has also been modified: the block used for this purpose is smaller than in conventional instruments and it is maintained at a constant, strictly controlled temperature. As a result of the technical and analytical improvements, the currently being tested prototypes of PCR|ONE are able to complete DNA assays in less than 15 minutes, and the PCR itself takes only 7 minutes. The first PCR|ONE devices are expected to be commercially available in 2-3 years.

"Our DNA testing technique has been patented. However, we want to emphasize the freedom of using it for non-commercial purposes," said Prof. Garstecki.

The study, by Debski PR et al, was published March 22, 2017, in the journal Scientific Reports.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System

Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Galleri is designed to detect cancer-specific methylation patterns across multiple cancer types before symptoms appear, including cancers without recommended screening (Photo courtesy of GRAIL)

Multi-Cancer Early Detection Test Wins FDA Panel Backing for Approval

GRAIL’s Galleri multi-cancer early detection (MCED) test was reviewed by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration’s (FDA) Medical Devices Advisory Committee.... Read more